Clinical Report: 2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Overview

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD, discuss PANKU-Breast02 results for izalontamab brengitecan (iza-bren) in metastatic triple-negative breast cancer. The supplied article context does not include trial design, numerical outcomes, or safety findings, so these results cannot be summarized in further detail.

Background

Metastatic triple-negative breast cancer is the clinical setting addressed by PANKU-Breast02. The supplied context identifies iza-bren as a dual-antibody drug conjugate under discussion at the 2026 ASCO meeting. Web research context describes iza-bren as a bispecific antibody–drug conjugate targeting EGFR and HER3 and delivering a topoisomerase-I inhibitor. The provided materials do not specify the study population, comparator, treatment line, or detailed efficacy and safety results.

Data Highlights

No numerical PANKU-Breast02 data are provided in the supplied article context. The web research context reports that the study presented late-breaking results but does not provide trial-specific estimates or endpoints.

Key Findings

• PANKU-Breast02 concerns izalontamab brengitecan (iza-bren) in metastatic triple-negative breast cancer.
• Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD, discuss the study results in the article context.
• The article context characterizes iza-bren as a dual-antibody drug conjugate.
• The web research context describes iza-bren as a bispecific ADC targeting EGFR and HER3 and delivering a topoisomerase-I inhibitor.
• The supplied materials do not report PANKU-Breast02 enrollment, comparator, efficacy estimates, or adverse-event data.

Clinical Implications

The supplied information identifies iza-bren as an investigational treatment discussed for metastatic triple-negative breast cancer but does not provide enough trial detail to assess its clinical role. No treatment recommendation can be derived from the provided PANKU-Breast02 context.

Conclusion

PANKU-Breast02 was highlighted at ASCO 2026 in a discussion of iza-bren for metastatic triple-negative breast cancer. Trial-specific outcomes and safety findings are not available in the supplied source material.

Related Resources & Content

1. Bristol Myers Squibb, Company announcement, 2026 -- Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
2. ASCO Publications — A pan-cancer analysis of P21 activated kinase (PAK) family genes as potential biomarkers for immune checkpoint therapy.
3. ASCO Publications — ENLIGHT: Pancancer response prediction to targeted and immunotherapies via tumor transcriptomics.
4. ASCO Publications — Enhanced surveillance modalities and biopsy outcomes.
5. ASCO Publications — Pan-cancer multi-omic integration for identification of clinically aggressive and potentially actionable molecular modules in breast, endometrial, and ovarian cancers.
6. Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
7. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer | FDA